As outcomes-based contracts gain attention

Harvard Pilgrim Agrees To Pay Amgen Based On Cholesterol Rx Outcomes

By John Wilkerson
November 11, 2015 at 5:31 PM
With an HHS drug pricing forum a week away, Harvard Pilgrim announced Monday (Nov. 9) an outcomes-based pricing contract with Amgen for cholesterol drugs in return preferential treatment of Amgen's drug. Plans, brand drug makers and government officials increasingly are talking about such contracts as the way to deal with the rising cost of specialty drugs, and HHS expressly mentioned outcomes-based pay models as a topic it wants to discuss at the upcoming drug forum. Amgen agreed to discount cholesterol...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on the coming Democrat-controlled House of Representatives, drug pricing reforms, Medicaid policy, FDA news and much more.